Venetoclax-Based Therapy Versus Intensive Chemotherapy Followed By Allogeneic-Stem Cell Transplantation for High-Risk Elderly Acute Myeloid LeukemiaAlexandre Iat, Sylvain Garciaz, Jan Philipp Bewersdorf et al.|Blood|2024Cited by 2
Comparative Analysis of Outcomes with HMA Plus Venetoclax Vs Intensive Chemotherapy in AML Patients Harboring Very-High Risk CytogeneticsLuis E. Aguirre, Maximilian Stahl, Jan Philipp Bewersdorf et al.|Blood|2024Cited by 1
Redefining Clinical Response Criteria in Myelodysplastic Syndromes to Better Forecast Post-Transplant OutcomesLuis E. Aguirre, Maximilian Stahl, Haesook T. Kim et al.|Blood|2024Cited by 0
The Prognostic and Predictive Value of <i>RUNX1</i> Mutations in Newly Diagnosed Acute Myeloid Leukemia - an International Multicenter Cohort StudyRebecca P. Bystrom, Maximilian Stahl, Jan Philipp Bewersdorf et al.|Blood|2024Cited by 0
Impact of Molecular Ontogeny on Hematological Recovery in AML Patients Treated with Hypomethylating Agent Plus Venetoclax TherapyJ. P. Zhang, Maximilian Stahl, Shai Shimony et al.|Blood|2024Cited by 0